Navigation Links
Lexicon to Present at Stifel Nicolaus Healthcare Conference
Date:9/9/2010

THE WOODLANDS, Texas, Sept. 9 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 16, 2010 at 9:10 a.m. Eastern Time.

A live webcast of the presentation will be accessible through Lexicon's corporate website at www.lexpharma.com. An archived edition of the presentation will also be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon to Present at Two Major Healthcare Investor Conferences
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
5. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
6. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
8. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
9. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
10. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
11. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Pa., Sept. 7, 2011 Tengion, Inc (NASDAQ: ... Brian Davis, Vice President and Chief Financial Officer of Tengion, ... Healthcare Conference on Tuesday, September 13, 2011, at 1:35 pm ... can be accessed under "Calendar of Events" in the Investors ...
... 2011 The Journal of Cell Biology ... pleased to announce their next enhancement to the JCB ... published scientific image data. Starting today, data from genome-wide ... with papers published in JCB. HCS data are increasingly ...
... 7, 2011 Debiopharm Group™ ... focuses on serious medical conditions and particularly ... privately-held, biopharmaceutical company dedicated to the discovery ... cancer, have entered into an exclusive worldwide ...
Cached Biology Technology:Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 3Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 2Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 3
(Date:4/16/2014)... ,, Sometimes known as Kennedy,s disease, spinal and bulbar muscular ... slowly progressive muscle weakness and atrophy. Researchers have long considered ... the cells in the spinal cord and brainstem that ... in the April 16, 2014 online issue of Neuron ...
(Date:4/16/2014)... thoughts and feelings are the result of neurons talking ... of the conversations might not be all that private. Brain ... even participating in, some of those discussions. But a new ... part of the time specifically, when the neurons get ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3Gate for bacterial toxins found 2
... the president of Conservation International and a global leader ... Medal from the Harvard Museum of Natural History. ... who has written more than 500 scientific and popular ... has described 11 species new to science, had seven ...
... Scientists at UC Santa Barbara have made a significant discovery ... They explain nature,s way of controlling whether these cells will ... a liver, or any other part of the human body. ... the journal Cell . The scientists say the ...
... a successful second funding period, the first three DFG ... for another four years. This decision was made by ... Research Foundation) at its spring session in Bonn. As ... in the Earth System" in Bremen, "The Center for ...
Cached Biology News:Scientists shed light on inner workings of human embryonic stem cells 2Scientists shed light on inner workings of human embryonic stem cells 3The first DFG research centers to be funded for another four years 2The first DFG research centers to be funded for another four years 3The first DFG research centers to be funded for another four years 4
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
...
... a dedicated system for SFC and SFE ... of HPLC instrumentation. JASCO has recently added ... of the system: ,- The PU-1580-CO2 delivery ... procedures using carbon dioxide as the mobile ...
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
Biology Products: